glp-1 obesity drug news today A wave of new #GLP1 options for type 2 #Diabetes and #Obesity was a major focus at #ADA2026. In the latest JAMA Medical podcast, Jennifer Abbasi interviews Rita Kalyani, MD GLP-1 drugs: FDA approvals and

Aggregation-triggering segments of SOD1 fibril formation support a common pathway for familial and sporadic ALS

April 24, 2026 DSIP antioxidant research covering oxidative stress modulation, antioxidant enzyme activity, lipid peroxidation, and mitochondrial oxidative stress

diosgenin, charantin, and hydroxychalcone from the formulations F1 and F2, the relative bioavailabilities for these were calculated and the results are presented in Table 9

Contact us today to learn more about the practice and all of the services we offer in Naples, Fort Myers, Bonita Beach, Miami, and Orlando, Florida

Depending on your IBS subtype and symptoms, GLP-1s may either improve or aggravate gastrointestinal symptoms such as bloating, constipation, urgency or abdominal pain

Unlike traditional dieting, which often causes muscle loss along with fat loss, body recomposition aims to improve the overall shape and composition of the body